NZ Lymphoma / Leukaemia Research Review Issue 15

In this issue:
Leukaemia selection

• Monitoring of minimal residual disease in NPM1-mutated AML
•   Chimeric antigen receptor-modified T-cells in CLL
•   Nonmyeloablative conditioning with allogeneic HSCT for high-risk ALL

Lymphoma selection
• ABVD vs. BEACOPP for HL with planned high-dose salvage
•   Reduced intensity allogeneic HSCT induces remission in relapsed HL
•   Effects of statins, metformin and aspirin on rituximab-treated DLBCL
•   Alemtuzumab in LPL/Waldenström macroglobulinaemia
•   R-miniCHOP in elderly patients with DLBCL
•   Bortezomib added to R-CVP in advanced-stage FL
•   Bortezomib, bendamustine and rituximab in relapsed/refractory FL

Please login below to download this issue (PDF)

Subscribe